trial · primary record
Telisotuzumab Adizutecan
Head and Neck Squamous Cell Carcinoma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 150 |
| Primary completion | 2029-10 |
| Primary endpoint | Number of Participants with Adverse Events (AE)s |
| Registry ID | NCT07744126 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T02:32:34.193Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07744126
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.